Fig. 2: Flowchart of patients receiving sequencing results and/or discussed in Molecular Tumour board (MTB).

GMT genetically matched therapy, MAB monoclonal antibodies, PARPi PARP inhibitors, PD-(L)1i programmed death(-ligand) 1 inhibitors, PORCNi porcupine inhibitors, TKI tyrosine kinase inhibitors.